title: Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein.
abstract: OBJECTIVE
  To compare the therapeutic effect and significances of multimodality treatment for hepatocellular carcinoma (HCC) with tumor thrombi in portal vein (PVTT).
  
  
  METHODS
  HCC patients (n=147) with tumor thrombi in the main portal vein or the first branch of portal vein were divided into four groups by the several therapeutic methods. There were conservative treatment group in 18 out of patients (group A); and hepatic artery ligation(HAL) and/or hepatic artery infusion (HAI) group in 18 patients (group B), in whom postoperative chemoembolization was done periodically; group of removal of HCC with PVTT in 79 (group C) and group of transcatheter hepatic arterial chemoembolization (TACE) or HAI and/or portal vein infusion (PVI) after operation in 32 (group D).
  
  
  RESULTS
  The median survival period was 12 months in our series and the 1-,3-, and 5-year survival rates were 44.3%, 24.5% and 15.2%, respectively. The median survival times were 2, 5, 12 and 16 months in group A, B, C and D, respectively. The 1-, 3- and 5-year survival rates were 5.6%, 0% and 0% in group A; 22.2%, 5.6% and 0% in group B; 53.9%, 26.9% and 16.6% in group C; 79.3%, 38.9% and 26.8% in group D, respectively. Significant difference appeared in the survival rates among the groups (P < 0.05).
  
  
  CONCLUSIONS
  Hepatic resection with removal of tumor thrombi and HCC should increase the curative effects and be encouraged for the prolongation of life span and quality of life for HCC patients with PVTT, whereas the best therapeutic method for HCC with PVTT is with regional hepatic chemotherapy or chemoembolization after hepatic resection with removal of tumor thrombi.
authors.affiliation: Liver Cancer Institute, Zhongshan Hospital, Fudan University Medical Center,136 Yixueyuan Road, Shanghai 200032,China. jiafan 99 @ yahoo.com
authors.forename: J
authors.initials: J
authors.lastname: Fan
authors.forename: Z Q
authors.initials: ZQ
authors.lastname: Wu
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Tang
authors.forename: J
authors.initials: J
authors.lastname: Zhou
authors.forename: S J
authors.initials: SJ
authors.lastname: Qiu
authors.forename: Z C
authors.initials: ZC
authors.lastname: Ma
authors.forename: X D
authors.initials: XD
authors.lastname: Zhou
authors.forename: S L
authors.initials: SL
authors.lastname: Ye
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D005260:Female; D006499:Hepatic Artery / Q000601:surgery; D006801:Humans; D008026:Ligation; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating; D011169:Portal Vein; D011379:Prognosis; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents